公开(公告)号：US20120183471A1

公开(公告)日：2012-07-19

申请号：US13201061

申请日：2010-02-17

申请人： Lloyd J. Old ,  Constance Old ,  Andrew Mark Scott ,  Gerd Ritter ,  Achim Jungbluth ,  Elisabeth Stockert ,  Stephen Stockert ,  Vincent Peter Collins ,  Webster K. Cavenee ,  Huei-Jen Su Huang ,  Antony Wilks Burgess ,  Edouard Collins Nice ,  Anne Murray ,  George Mark ,  Terrance Grant Johns ,  Con Panousis ,  Christoph Renner

发明人： Lloyd J. Old ,  Constance Old ,  Andrew Mark Scott ,  Gerd Ritter ,  Achim Jungbluth ,  Elisabeth Stockert ,  Stephen Stockert ,  Vincent Peter Collins ,  Webster K. Cavenee ,  Huei-Jen Su Huang ,  Antony Wilks Burgess ,  Edouard Collins Nice ,  Anne Murray ,  George Mark ,  Terrance Grant Johns ,  Con Panousis ,  Christoph Renner

IPC分类号： A61K39/395 ,  A61P35/00 ,  C12N1/19 ,  G01N33/574 ,  C12N5/10 ,  C12N1/21 ,  C07K16/30 ,  A61K51/00

CPC分类号： C07K16/40 ,  A61K31/495 ,  A61K39/39541 ,  A61K39/39558 ,  A61K47/6871 ,  A61K51/103 ,  A61K51/1045 ,  A61K51/1078 ,  A61K2039/505 ,  A61K2300/00 ,  C07K16/2863 ,  C07K16/30 ,  C07K16/4258 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/51 ,  C07K2317/515 ,  C07K2317/52 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/77 ,  C07K2317/92

摘要： The present invention relates to specific binding members, particularly antibodies and fragments thereof, which bind to amplified epidermal growth factor receptor (EGFR) and to the de2-7 EGFR truncation of the EGFR. In particular, the epitope recognized by the specific binding members, particularly antibodies and fragments thereof, is enhanced or evident upon aberrant post-translational modification. These specific binding members are useful in the diagnosis and treatment of cancer. The binding members of the present invention may also be used in therapy in combination with chemotherapeutics or anti-cancer agents and/or with other antibodies or fragments thereof.

摘要翻译： 本发明涉及结合扩增的表皮生长因子受体（EGFR）和EGFR的de2-7 EGFR截短的特异性结合成员，特别是抗体及其片段。 特别地，特异性结合成员识别的表位，特别是其抗体及其片段，在异常翻译后修饰时增强或明显。 这些特异性结合成员可用于癌症的诊断和治疗。 本发明的结合成员也可用于与化学治疗剂或抗癌剂和/或与其它抗体或其片段组合的治疗中。

公开(公告)号：US20110076232A1

公开(公告)日：2011-03-31

申请号：US12890029

申请日：2010-09-24

申请人： Lloyd J. Old ,  Terrance Grant Johns ,  Con Panousis ,  Andrew Mark Scott ,  Christoph Renner ,  Achim Jungbluth ,  Elizabeth Stockert ,  Vincent Peter Collins ,  Webster K. Cavenee ,  Huei-Jen Su Huang ,  Antony Wilks Burgess ,  Edouard Collins Nice ,  Anne Murray ,  George Mark ,  Gerd Ritter

发明人： Lloyd J. Old ,  Terrance Grant Johns ,  Con Panousis ,  Andrew Mark Scott ,  Christoph Renner ,  Achim Jungbluth ,  Elizabeth Stockert ,  Vincent Peter Collins ,  Webster K. Cavenee ,  Huei-Jen Su Huang ,  Antony Wilks Burgess ,  Edouard Collins Nice ,  Anne Murray ,  George Mark ,  Gerd Ritter

IPC分类号： A61K51/10 ,  C07K16/28 ,  A61K39/395 ,  A61P35/00

CPC分类号： C07K16/2863 ,  A61K39/39558 ,  A61K51/103 ,  A61K51/1045 ,  A61K2039/505 ,  A61K2039/507 ,  A61K2039/545 ,  C07K16/30 ,  C07K16/4266 ,  C07K2317/24 ,  C07K2317/32 ,  C07K2317/34 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/76 ,  C07K2317/77 ,  C07K2317/92 ,  C07K2317/94 ,  A61K2300/00

摘要： The present invention relates to specific binding members, particularly antibodies and fragments thereof, which bind to amplified epidermal growth factor receptor (EGFR) and to the de2-7 EGFR truncation of the EGFR. In particular, the epitope recognized by the specific binding members, particularly antibodies and fragments thereof, is enhanced or evident upon aberrant post-translational modification. These specific binding members are useful in the diagnosis and treatment of cancer. The binding members of the present invention may also be used in therapy in combination with chemotherapeutics or anti-cancer agents and/or with other antibodies or fragments thereof.

摘要翻译： 本发明涉及结合扩增的表皮生长因子受体（EGFR）和EGFR的de2-7 EGFR截短的特异性结合成员，特别是抗体及其片段。 特别地，特异性结合成员识别的表位，特别是其抗体及其片段，在异常翻译后修饰时增强或明显。 这些特异性结合成员可用于癌症的诊断和治疗。 本发明的结合成员也可用于与化学治疗剂或抗癌剂和/或与其它抗体或其片段组合的治疗中。

公开(公告)号：US20110293511A1

公开(公告)日：2011-12-01

申请号：US13078781

申请日：2011-04-01

申请人： Terrance Grant Johns ,  Andrew Mark Scott ,  Gerd Ritter ,  Achim Jungbluth ,  Elizabeth Stockert ,  Vincent Peter Collins ,  Webster K. Cavenee ,  Huei-Jen Su Huang ,  Antony Wilks Burgess ,  Edouard Collins Nice ,  Anne Murray ,  George Mark ,  Lloyd J. Old ,  Edward B. Reilly ,  Andrew C. Phillips ,  Jonathan A. Meulbroek ,  Fritz G. Buchanan ,  Stephen Stockert

发明人： Terrance Grant Johns ,  Andrew Mark Scott ,  Gerd Ritter ,  Achim Jungbluth ,  Elizabeth Stockert ,  Vincent Peter Collins ,  Webster K. Cavenee ,  Huei-Jen Su Huang ,  Antony Wilks Burgess ,  Edouard Collins Nice ,  Anne Murray ,  George Mark ,  Lloyd J. Old ,  Edward B. Reilly ,  Andrew C. Phillips ,  Jonathan A. Meulbroek ,  Fritz G. Buchanan ,  Stephen Stockert

IPC分类号： A61K39/395 ,  A61K38/21 ,  A61K38/20 ,  A61K103/20 ,  A61K103/40 ,  A61K103/30 ,  A61K103/32 ,  A61K103/00 ,  A61P35/00

CPC分类号： C07K16/4266 ,  A61K39/39558 ,  A61K51/103 ,  A61K51/1045 ,  A61K2039/505 ,  A61K2039/507 ,  A61K2039/545 ,  C07K16/2863 ,  C07K16/30 ,  C07K2317/24 ,  C07K2317/32 ,  C07K2317/34 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/76 ,  C07K2317/77 ,  C07K2317/92 ,  C07K2317/94 ,  A61K2300/00

摘要： The present invention relates to specific binding members, particularly antibodies and fragments thereof, which bind to EGFR on tumor cells that overexpress EGFR, and on tumor cells that express the truncated version of the EGFR receptor, de2-7 EGF. In particular, the epitope recognized by the specific binding members, particularly antibodies and fragments thereof, is enhanced or evident upon aberrant post-translational modification. These specific binding members are useful in the diagnosis and treatment of cancer. The binding members of the present invention may also be used in therapy in combination with chemotherapeutics or anti-cancer agents and/or with other antibodies or fragments thereof.

公开(公告)号：US07589180B2

公开(公告)日：2009-09-15

申请号：US10145598

申请日：2002-05-13

申请人： Lloyd J. Old ,  Terrance Grant Johns ,  Con Panousis ,  Andrew Mark Scott ,  Christoph Renner ,  Gerd Ritter ,  Achim Jungbluth ,  Elisabeth Stockert ,  Peter Collins ,  Webster K. Cavenee ,  Huei-Jen Su Huang ,  Antony Wilks Burgess ,  Edouard Collins Nice

发明人： Lloyd J. Old ,  Terrance Grant Johns ,  Con Panousis ,  Andrew Mark Scott ,  Christoph Renner ,  Gerd Ritter ,  Achim Jungbluth ,  Elisabeth Stockert ,  Peter Collins ,  Webster K. Cavenee ,  Huei-Jen Su Huang ,  Antony Wilks Burgess ,  Edouard Collins Nice

IPC分类号： C07K16/28

CPC分类号： C07K16/2863 ,  A61K39/395 ,  A61K39/39541 ,  A61K45/06 ,  A61K2039/505 ,  C07K2317/34 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/77 ,  A61K2300/00

摘要： The invention relates to specific binding members, particularly antibodies and active fragments thereof, which recognize an aberrant post-translationally modified, particularly an aberrant glycosylated form of the EGFR. The binding members, particularly antibodies and fragments thereof, of the invention do not bind to EGFR on normal cells in the absence of amplification of the wild-type gene and are capable of binding the de2-7 EGFR at an epitope which is distinct from the junctional peptide. Antibodies of this type are exemplified by the novel antibody 806 whose VH and VL sequences are illustrated as SEQ ID NOs: 2 and 4 and chimeric antibodies thereof as exemplified by ch806.

公开(公告)号：US20090137782A1

公开(公告)日：2009-05-28

申请号：US10145598

申请日：2002-05-13

申请人： Lloyd J. Old ,  Terrance Grant Johns ,  Con Panousis ,  Andrew Mark Scott ,  Christoph Renner ,  Gerd Ritter ,  Achim Jungbluth ,  Elisabeth Stockert ,  V. Peter Collins ,  Webster K. Cavenee ,  Huei-Jen Su Huang ,  Antony Wilks Burgess ,  Edouard Collins Nice

发明人： Lloyd J. Old ,  Terrance Grant Johns ,  Con Panousis ,  Andrew Mark Scott ,  Christoph Renner ,  Gerd Ritter ,  Achim Jungbluth ,  Elisabeth Stockert ,  V. Peter Collins ,  Webster K. Cavenee ,  Huei-Jen Su Huang ,  Antony Wilks Burgess ,  Edouard Collins Nice

IPC分类号： C07K16/30

CPC分类号： C07K16/2863 ,  A61K39/395 ,  A61K39/39541 ,  A61K45/06 ,  A61K2039/505 ,  C07K2317/34 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/77 ,  A61K2300/00

摘要： The invention relates to specific binding members, particularly antibodies and active fragments thereof, which recognize an aberrant post-translationally modified, particularly an aberrant glycosylated form of the EGFR. The binding members, particularly antibodies and fragments thereof, of the invention do not bind to EGFR on normal cells in the absence of amplification of the wild-type gene and are capable of binding the de2-7 EGFR at an epitope which is distinct from the junctional peptide. Antibodies of this type are exemplified by the novel antibody 806 whose VH and VL sequences are illustrated as SEQ ID NOs: 2 and 4 and chimeric antibodies thereof as exemplified by ch806.

摘要翻译： 本发明涉及特异性结合成员，特别是抗体及其活性片段，其识别异常翻译后修饰，特别是EGFR的异常糖基化形式。 本发明的结合成员，特别是抗体及其片段在正常细胞上不与野生型基因扩增结合，并且能够以不同于 连接肽。 这种抗体的例子是其VH和VL序列如SEQ ID NO：2和4以及其嵌合抗体如ch806所示的新抗体806。

公开(公告)号：US20110313230A1

公开(公告)日：2011-12-22

申请号：US13078764

申请日：2011-04-01

申请人： Terrance Grant Johns ,  Andrew Mark Scott ,  Gerd Ritter ,  Achim Jungbluth ,  Elizabeth Stockert ,  Stephen Stockert ,  Vincent Peter Collins ,  Webster K. Cavenee ,  Huei-Jen Su Huang ,  Antony Wilks Burgess ,  Edouard Collins Nice ,  Anne Murray ,  George Mark ,  Lloyd J. Old ,  Edward B. Reilly ,  Andrew C. Phillips ,  Jonathan A. Meulbroek ,  Fritz G. Buchanan

发明人： Terrance Grant Johns ,  Andrew Mark Scott ,  Gerd Ritter ,  Achim Jungbluth ,  Elizabeth Stockert ,  Stephen Stockert ,  Vincent Peter Collins ,  Webster K. Cavenee ,  Huei-Jen Su Huang ,  Antony Wilks Burgess ,  Edouard Collins Nice ,  Anne Murray ,  George Mark ,  Lloyd J. Old ,  Edward B. Reilly ,  Andrew C. Phillips ,  Jonathan A. Meulbroek ,  Fritz G. Buchanan

IPC分类号： A61N5/00 ,  A61K38/19 ,  A61P35/00 ,  A61K51/00 ,  A61K38/21 ,  A61K39/395 ,  A61K38/20

CPC分类号： A61K39/3955 ,  A61K39/39541 ,  A61K39/39558 ,  A61K45/06 ,  A61K51/103 ,  A61K51/1045 ,  A61K51/1078 ,  A61K2039/505 ,  A61K2039/507 ,  C07K16/22 ,  C07K16/2863 ,  C07K16/30 ,  C07K16/4241 ,  C07K16/4258 ,  C07K16/4266 ,  C07K2299/00 ,  C07K2317/24 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/77 ,  C07K2317/90 ,  C07K2317/92 ,  A61K2300/00

摘要： The present invention relates to specific binding members, particularly antibodies and fragments thereof, which bind to EGFR on tumor cells that overexpress EGFR, and on tumor cells that express the truncated version of the EGFR receptor, de2-7 EGF. In particular, the epitope recognized by the specific binding members, particularly antibodies and fragments thereof, is enhanced or evident upon aberrant post-translational modification. These specific binding members are useful in the diagnosis and treatment of cancer. The binding members of the present invention may also be used in therapy in combination with chemotherapeutics or anti-cancer agents and/or with other antibodies or fragments thereof.

摘要翻译： 本发明涉及在过表达EGFR的肿瘤细胞上结合EGFR的特异性结合成员，特别是抗体及其片段，以及表达EGFR受体截短型de2-7EGF的肿瘤细胞。 特别地，特异性结合成员识别的表位，特别是其抗体及其片段，在异常翻译后修饰时增强或明显。 这些特异性结合成员可用于癌症的诊断和治疗。 本发明的结合成员也可用于与化学治疗剂或抗癌剂和/或与其它抗体或其片段组合的治疗中。

公开(公告)号：US09045533B2

公开(公告)日：2015-06-02

申请号：US14037504

申请日：2013-09-26

申请人： Gerd Ritter ,  Beatrice Yin ,  Anne Murray ,  George Mark ,  Lloyd J. Old ,  Kenneth Lloyd ,  Serhiy Souchelnytskiy ,  Ivan Gout ,  Valeriy Filonenko ,  Ramziya Kiyamova

发明人： Gerd Ritter ,  Beatrice Yin ,  Anne Murray ,  George Mark ,  Lloyd J. Old ,  Kenneth Lloyd ,  Serhiy Souchelnytskiy ,  Ivan Gout ,  Valeriy Filonenko ,  Ramziya Kiyamova

IPC分类号： C12P21/08 ,  C12N5/10 ,  C07K16/18 ,  C07K16/28 ,  C07K14/705 ,  C07K16/30 ,  A61K39/395 ,  C07K7/08 ,  C07K14/47 ,  A61K39/00

CPC分类号： C07K16/3069 ,  A61K39/00 ,  A61K39/0011 ,  A61K39/39558 ,  A61K2039/505 ,  A61K2039/53 ,  C07K7/08 ,  C07K14/4748 ,  C07K14/705 ,  C07K16/18 ,  C07K16/28 ,  C07K16/30 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/622 ,  G01N33/57449 ,  G01N2333/705 ,  G01N2500/04

摘要： The present disclosure relates generally to the membrane transporter NaPi2b (SLC34A2) as a target for therapy, including immunotherapy, and particularly cancer therapy. The SLC34A2 epitope peptide encompassing amino acids 312-340 of SLC34A2 has been identified as an ovarian cancer epitope using the monoclonal antibody MX35. The invention also relates to the use of SLC34A2 and particularly SLC34A2 peptides in generating antibodies which have anti-tumor or anti-cancer activity or in stimulating an immunological response. The invention further relates to antibodies specifically directed against NaPi2b (SLC34A2) and the SLC34A2 peptide(s), including veneered, chimeric, single chain and humanized antibodies. Methods for generating an immune response and for treatment of tumors and cancer are also provided. Assays for screening and identifying compounds directed against SLC34A2, including the SLC34A2 epitope peptide, and additional antibodies are provided.

摘要翻译： 本公开总体上涉及作为治疗靶标的膜转运体NaPi2b（SLC34A2），包括免疫治疗，特别是癌症治疗。 包含SLC34A2的氨基酸312-340的SLC34A2表位肽已经使用单克隆抗体MX35鉴定为卵巢癌表位。 本发明还涉及SLC34A2和特别是SLC34A2肽在产生具有抗肿瘤或抗癌活性或刺激免疫应答的抗体中的用途。 本发明进一步涉及特异性针对NaPi2b（SLC34A2）和SLC34A2肽的抗体，包括贴面，嵌合，单链和人源化抗体。 还提供了产生免疫应答和治疗肿瘤和癌症的方法。 提供筛选和鉴定针对SLC34A2的化合物，包括SLC34A2表位肽和其他抗体的测定。

公开(公告)号：US20160009816A1

公开(公告)日：2016-01-14

申请号：US14693261

申请日：2015-04-22

申请人： Gerd Ritter ,  Beatrice Yin ,  Anne Murray ,  George Mark ,  Lloyd J. Old ,  Kenneth Lloyd ,  Serhiy Souchelnytskiy ,  Ivan Gout ,  Valeriy Filonenko ,  Ramziya Kiyamova

发明人： Gerd Ritter ,  Beatrice Yin ,  Anne Murray ,  George Mark ,  Lloyd J. Old ,  Kenneth Lloyd ,  Serhiy Souchelnytskiy ,  Ivan Gout ,  Valeriy Filonenko ,  Ramziya Kiyamova

IPC分类号： C07K16/30 ,  A61K39/00 ,  G01N33/574 ,  C07K14/705

CPC分类号： C07K16/3069 ,  A61K39/00 ,  A61K39/0011 ,  A61K39/39558 ,  A61K2039/505 ,  A61K2039/53 ,  C07K7/08 ,  C07K14/4748 ,  C07K14/705 ,  C07K16/18 ,  C07K16/28 ,  C07K16/30 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/622 ,  G01N33/57449 ,  G01N2333/705 ,  G01N2500/04

摘要： The present invention relates generally to the membrane transporter NaPi2b (SLC34A2) as a target for therapy, including immunotherapy, and particularly cancer therapy. The SLC34A2 epitope peptide encompassing amino acids 312-340 of SLC34A2 has been identified as an ovarian cancer epitope using the monoclonal antibody MX35. The invention also relates to the use of SLC34A2 and particularly SLC34A2 peptides in generating antibodies which have anti-tumor or anti-cancer activity or in stimulating an immunological response. The invention further relates to antibodies specifically directed against NaPi2b (SLC34A2) and the SLC34A2 peptide(s), including veneered, chimeric, single chain and humanized antibodies. Methods for generating an immune response and for treatment of tumors and cancer are also provided. Assays for screening and identifying compounds directed against SLC34A2, including the SLC34A2 epitope peptide, and additional antibodies are provided.

摘要翻译： 本发明一般涉及作为治疗靶标的膜转运体NaPi2b（SLC34A2），包括免疫治疗，特别是癌症治疗。 包含SLC34A2的氨基酸312-340的SLC34A2表位肽已经使用单克隆抗体MX35鉴定为卵巢癌表位。 本发明还涉及SLC34A2和特别是SLC34A2肽在产生具有抗肿瘤或抗癌活性或刺激免疫应答的抗体中的用途。 本发明进一步涉及特异性针对NaPi2b（SLC34A2）和SLC34A2肽的抗体，包括贴面，嵌合，单链和人源化抗体。 还提供了产生免疫应答和治疗肿瘤和癌症的方法。 提供筛选和鉴定针对SLC34A2的化合物，包括SLC34A2表位肽和其他抗体的测定。

公开(公告)号：US20170362336A1

公开(公告)日：2017-12-21

申请号：US15609839

申请日：2017-05-31

申请人： Gerd Ritter ,  Beatrice Yin ,  Anne Murray ,  George Mark ,  Lloyd J. Old ,  Kenneth Lloyd ,  Serhiy Souchelnytskiy ,  Ivan Gout ,  Valeriy Filonenko ,  Ramziya Kiyamova

发明人： Gerd Ritter ,  Beatrice Yin ,  Anne Murray ,  George Mark ,  Lloyd J. Old ,  Kenneth Lloyd ,  Serhiy Souchelnytskiy ,  Ivan Gout ,  Valeriy Filonenko ,  Ramziya Kiyamova

IPC分类号： C07K16/30 ,  A61K39/00 ,  A61K39/395 ,  G01N33/574 ,  C07K14/47 ,  C07K14/705 ,  C07K16/18 ,  C07K16/28 ,  C07K7/08

CPC分类号： C07K16/3069 ,  A61K39/00 ,  A61K39/0011 ,  A61K39/39558 ,  A61K2039/505 ,  A61K2039/53 ,  C07K7/08 ,  C07K14/4748 ,  C07K14/705 ,  C07K16/18 ,  C07K16/28 ,  C07K16/30 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/622 ,  G01N33/57449 ,  G01N2333/705 ,  G01N2500/04

摘要： The present invention relates generally to the membrane transporter NaPi2b (SLC34A2) as a target for therapy, including immunotherapy, and particularly cancer therapy. The SLC34A2 epitope peptide encompassing amino acids 312-340 of SLC34A2 has been identified as an ovarian cancer epitope using the monoclonal antibody MX35. The invention also relates to the use of SLC34A2 and particularly SLC34A2 peptides in generating antibodies which have anti-tumor or anti-cancer activity or in stimulating an immunological response. The invention further relates to antibodies specifically directed against NaPi2b (SLC34A2) and the SLC34A2 peptide(s), including veneered, chimeric, single chain and humanized antibodies. Methods for generating an immune response and for treatment of tumors and cancer are also provided. Assays for screening and identifying compounds directed against SLC34A2, including the SLC34A2 epitope peptide, and additional antibodies are provided.

公开(公告)号：US20140193417A1

公开(公告)日：2014-07-10

申请号：US14037504

申请日：2013-09-26

申请人： Gerd Ritter ,  Beatrice Yin ,  Anne Murray ,  George Mark ,  Lloyd J. Old ,  Kenneth Lloyd ,  Serhiy Souchelnytskiy ,  Ivan Gout ,  Valeriy Filonenko ,  Ramziya Kiyamova

发明人： Gerd Ritter ,  Beatrice Yin ,  Anne Murray ,  George Mark ,  Lloyd J. Old ,  Kenneth Lloyd ,  Serhiy Souchelnytskiy ,  Ivan Gout ,  Valeriy Filonenko ,  Ramziya Kiyamova

IPC分类号： C07K16/18 ,  A61K39/00 ,  C07K7/08 ,  A61K39/395 ,  C07K14/47

CPC分类号： C07K16/3069 ,  A61K39/00 ,  A61K39/0011 ,  A61K39/39558 ,  A61K2039/505 ,  A61K2039/53 ,  C07K7/08 ,  C07K14/4748 ,  C07K14/705 ,  C07K16/18 ,  C07K16/28 ,  C07K16/30 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/622 ,  G01N33/57449 ,  G01N2333/705 ,  G01N2500/04

摘要： The present disclosure relates generally to the membrane transporter NaPi2b (SLC34A2) as a target for therapy, including immunotherapy, and particularly cancer therapy. The SLC34A2 epitope peptide encompassing amino acids 312-340 of SLC34A2 has been identified as an ovarian cancer epitope using the monoclonal antibody MX35. The invention also relates to the use of SLC34A2 and particularly SLC34A2 peptides in generating antibodies which have anti-tumor or anti-cancer activity or in stimulating an immunological response. The invention further relates to antibodies specifically directed against NaPi2b (SLC34A2) and the SLC34A2 peptide(s), including veneered, chimeric, single chain and humanized antibodies. Methods for generating an immune response and for treatment of tumors and cancer are also provided. Assays for screening and identifying compounds directed against SLC34A2, including the SLC34A2 epitope peptide, and additional antibodies are provided.

摘要翻译： 本公开总体上涉及作为治疗靶标的膜转运体NaPi2b（SLC34A2），包括免疫治疗，特别是癌症治疗。 包含SLC34A2的氨基酸312-340的SLC34A2表位肽已经使用单克隆抗体MX35鉴定为卵巢癌表位。 本发明还涉及SLC34A2和特别是SLC34A2肽在产生具有抗肿瘤或抗癌活性或刺激免疫应答的抗体中的用途。 本发明进一步涉及特异性针对NaPi2b（SLC34A2）和SLC34A2肽的抗体，包括贴面，嵌合，单链和人源化抗体。 还提供了产生免疫应答和治疗肿瘤和癌症的方法。 提供筛选和鉴定针对SLC34A2的化合物，包括SLC34A2表位肽和其他抗体的测定。